NovoCure Limited Stock 12‑Month Price Target Raised to $22.2, Implies 52% Upside

NovoCure Limited's average stock price target increased to $22.2 from $21.33, with a range of $15 to $29, according to 5 analysts. This implies a 52% upside from the Nov. 4 closing price. The consensus rating remains 'Buy' among 6 analysts, with 3 Buys and 3 Holds.

Original reporting
Published Nov 5, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NovoCure Limited Stock 12‑Month Price Target Raised to $22.2, Implies 52% Upside — source image
Decision brief

The 30-second read

$NVCRBullishLow
01

Why it matters

Analyst target revisions can move the stock modestly, but without a new catalyst the effect may be short‑lived.

02

Market read

Price target update provides a small signal for traders, but limited actionable insight.

03

What to watch

No new clinical data released; price target change reflects analyst optimism rather than concrete catalyst.

Relevance 4/10Novelty 3/10Timing: today

Background

NovoCure is a biotech focused on cancer immunotherapy; its stock is volatile around trial news.

Company-level read

Ticker impact

$NVCRBullishMedium confidence
Context

Analyst consensus price target for NovoCure raised to $22.2, implying ~52% upside from the latest close.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Five analysts increased their median target; no new corporate event, just revised expectations.

Market effects

May lift sentiment in the oncology biotech sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

Target raise could be premature if upcoming trial data disappoint.

Key entities

  • NovoCure Limited

    Biotech firm developing immunotherapy treatments.

Related articles

$NVCRLowAI 8/10

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

Novocure (NVCR) announced that JAMA Network Open published results from the PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The trial met its primary endpoint, showing improved overall survival. Secondary endpoints also demonstrated significant benefits in pain management and quality of life. TTFields therapy was well-tolerated with no new safety signals. Novocure aims to inform clinicians and patients with these findings.

$NVCRMedAI 8/10

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

NovoCure's (NVCR) shares fell 6% after the FDA rejected its Optune Mya device for lung cancer brain metastases, citing uncertainty about clinical benefits. The company plans to meet with FDA officials to discuss a potential approval path. NovoCure's other Optune devices, Gio, Lua, and Pax, are approved and generating revenue, but the company remains unprofitable. The FDA's decision adds to investor concerns about competition from Revolution Medicines' Rasonque pill.

$NVCRHighAI 9/10

Novocure’s device for treating brain metastases rejected by FDA

The FDA rejected Novocure's PMA for Optune Mya, a device for treating brain metastases, citing uncertainty about clinical benefits. The FDA did not raise safety concerns. Novocure plans to discuss feedback with the FDA to explore approval options, but there is no guarantee of future approval. The company has FDA approvals for other TTFields therapies, including Optune Gio, Lua, and Pax.